Review of thoracic reirradiation with stereotactic body radiation therapy

A focus on toxicity risks

Michael T. Milano, Alina Mihai, Feng Ming Kong

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Reirradiation of thoracic malignancies is clinically challenging in balancing the risks and efficacy. Stereotactic body radiation therapy (SBRT) can facilitate ablative dosing of discrete targets while minimizing normal tissue exposure; thus, SBRT is an attractive, minimally invasive option to consider for patients with recurrent or new malignancies within a previously irradiated field. Published data are summarized from 28 studies on the use of SBRT for thoracic reirradiation. We review clinical outcomes with a primary focus on toxicity risks, dosimetric correlates of normal tissue complication probability (NTCP), and other factors that correlate with NTCP. Meaningful compilation of published data on reirradiation with SBRT is limited because of the retrospective nature of published studies, which include mostly small numbers of patients, with various clinical scenarios and SBRT dosing and techniques. Nevertheless, these studies show that thoracic reirradiation with SBRT is feasible, with relatively favorable outcomes. Yet, severe to fatal toxicities do occur, and dosimetric measures to predict severe toxicity are poorly characterized, necessitating further study to better characterize predictive factors for NTCP.

Original languageEnglish (US)
Pages (from-to)251-265
Number of pages15
JournalPractical Radiation Oncology
Volume8
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Radiotherapy
Thorax
Thromboplastin
Re-Irradiation
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Review of thoracic reirradiation with stereotactic body radiation therapy : A focus on toxicity risks. / Milano, Michael T.; Mihai, Alina; Kong, Feng Ming.

In: Practical Radiation Oncology, Vol. 8, No. 4, 01.07.2018, p. 251-265.

Research output: Contribution to journalReview article

Milano, Michael T. ; Mihai, Alina ; Kong, Feng Ming. / Review of thoracic reirradiation with stereotactic body radiation therapy : A focus on toxicity risks. In: Practical Radiation Oncology. 2018 ; Vol. 8, No. 4. pp. 251-265.
@article{3f91db2ce48845a6880264a0d943d2fa,
title = "Review of thoracic reirradiation with stereotactic body radiation therapy: A focus on toxicity risks",
abstract = "Reirradiation of thoracic malignancies is clinically challenging in balancing the risks and efficacy. Stereotactic body radiation therapy (SBRT) can facilitate ablative dosing of discrete targets while minimizing normal tissue exposure; thus, SBRT is an attractive, minimally invasive option to consider for patients with recurrent or new malignancies within a previously irradiated field. Published data are summarized from 28 studies on the use of SBRT for thoracic reirradiation. We review clinical outcomes with a primary focus on toxicity risks, dosimetric correlates of normal tissue complication probability (NTCP), and other factors that correlate with NTCP. Meaningful compilation of published data on reirradiation with SBRT is limited because of the retrospective nature of published studies, which include mostly small numbers of patients, with various clinical scenarios and SBRT dosing and techniques. Nevertheless, these studies show that thoracic reirradiation with SBRT is feasible, with relatively favorable outcomes. Yet, severe to fatal toxicities do occur, and dosimetric measures to predict severe toxicity are poorly characterized, necessitating further study to better characterize predictive factors for NTCP.",
author = "Milano, {Michael T.} and Alina Mihai and Kong, {Feng Ming}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.prro.2018.01.008",
language = "English (US)",
volume = "8",
pages = "251--265",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Review of thoracic reirradiation with stereotactic body radiation therapy

T2 - A focus on toxicity risks

AU - Milano, Michael T.

AU - Mihai, Alina

AU - Kong, Feng Ming

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Reirradiation of thoracic malignancies is clinically challenging in balancing the risks and efficacy. Stereotactic body radiation therapy (SBRT) can facilitate ablative dosing of discrete targets while minimizing normal tissue exposure; thus, SBRT is an attractive, minimally invasive option to consider for patients with recurrent or new malignancies within a previously irradiated field. Published data are summarized from 28 studies on the use of SBRT for thoracic reirradiation. We review clinical outcomes with a primary focus on toxicity risks, dosimetric correlates of normal tissue complication probability (NTCP), and other factors that correlate with NTCP. Meaningful compilation of published data on reirradiation with SBRT is limited because of the retrospective nature of published studies, which include mostly small numbers of patients, with various clinical scenarios and SBRT dosing and techniques. Nevertheless, these studies show that thoracic reirradiation with SBRT is feasible, with relatively favorable outcomes. Yet, severe to fatal toxicities do occur, and dosimetric measures to predict severe toxicity are poorly characterized, necessitating further study to better characterize predictive factors for NTCP.

AB - Reirradiation of thoracic malignancies is clinically challenging in balancing the risks and efficacy. Stereotactic body radiation therapy (SBRT) can facilitate ablative dosing of discrete targets while minimizing normal tissue exposure; thus, SBRT is an attractive, minimally invasive option to consider for patients with recurrent or new malignancies within a previously irradiated field. Published data are summarized from 28 studies on the use of SBRT for thoracic reirradiation. We review clinical outcomes with a primary focus on toxicity risks, dosimetric correlates of normal tissue complication probability (NTCP), and other factors that correlate with NTCP. Meaningful compilation of published data on reirradiation with SBRT is limited because of the retrospective nature of published studies, which include mostly small numbers of patients, with various clinical scenarios and SBRT dosing and techniques. Nevertheless, these studies show that thoracic reirradiation with SBRT is feasible, with relatively favorable outcomes. Yet, severe to fatal toxicities do occur, and dosimetric measures to predict severe toxicity are poorly characterized, necessitating further study to better characterize predictive factors for NTCP.

UR - http://www.scopus.com/inward/record.url?scp=85046169985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046169985&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2018.01.008

DO - 10.1016/j.prro.2018.01.008

M3 - Review article

VL - 8

SP - 251

EP - 265

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 4

ER -